Polymyalgia Rheumatica (PMR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Polymyalgia Rheumatica (PMR) Market Outlook

Thelansis’s “Polymyalgia Rheumatica (PMR) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Polymyalgia Rheumatica treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Polymyalgia Rheumatica (PMR) Overview

Polymyalgia rheumatica (PMR) is a prevalent inflammatory disorder of unknown origin that predominantly affects elderly individuals from Western countries. It is characterized by intense pain and stiffness involving the shoulders, proximal areas of the arms, neck, pelvic girdle, and proximal regions of the thighs. Patients with PMR commonly experience morning stiffness lasting more than 45 minutes and other non-specific symptoms like fatigue and malaise. Elevated acute phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are typical in PMR. The disease affects women two to three times more often than men and is often linked with giant cell arteritis (GCA), the most frequent vasculitis in elderly people in Western countries, which mainly affects the large and medium arteries, particularly the branches of the proximal aorta. Patients with PMR are typically over 50 years old and present with bilateral pain and stiffness in the shoulders, proximal aspects of the arms, neck, pelvic girdle, and thighs. The disease has an abrupt onset, usually within a few days. Morning stiffness lasts longer than 45 minutes in the affected areas, gradually improves throughout the day, and worsens after rest. Most individuals with polymyalgia rheumatica will receive treatment with oral corticosteroid medication.

• In the United Kingdom, PMR had an overall incidence rate of 95.9 per 100,000, with the highest incidence occurring in older age groups and women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: